Analysts Set Vera Therapeutics, Inc. (NASDAQ:VERA) Target Price at $64.67

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) have been assigned an average recommendation of "Buy" from the eleven analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and three have issued a strong buy recommendation on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $65.70.

Several equities research analysts have issued reports on the stock. HC Wainwright assumed coverage on shares of Vera Therapeutics in a research note on Monday. They set a "buy" rating and a $75.00 price target on the stock. Wolfe Research initiated coverage on shares of Vera Therapeutics in a research note on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 target price for the company. The Goldman Sachs Group began coverage on Vera Therapeutics in a research note on Tuesday, January 28th. They set a "buy" rating and a $58.00 price target on the stock. JPMorgan Chase & Co. dropped their target price on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a research note on Tuesday, March 4th. Finally, Guggenheim raised their price target on Vera Therapeutics from $59.00 to $61.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th.

Vera Therapeutics Price Performance

Shares of Vera Therapeutics stock traded down $3.52 during trading on Thursday, hitting $22.01. 4,144,052 shares of the company were exchanged, compared to its average volume of 769,396. Vera Therapeutics has a fifty-two week low of $18.53 and a fifty-two week high of $51.61. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. The firm has a 50 day moving average price of $24.63 and a 200 day moving average price of $35.06. The stock has a market capitalization of $1.40 billion, a price-to-earnings ratio of -8.43 and a beta of 1.28.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same quarter last year, the firm posted ($0.56) earnings per share. On average, equities analysts expect that Vera Therapeutics will post -2.89 earnings per share for the current fiscal year.

Institutional Trading of Vera Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Huntington National Bank acquired a new position in shares of Vera Therapeutics during the 4th quarter valued at $26,000. Summit Investment Advisors Inc. lifted its stake in shares of Vera Therapeutics by 16.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock worth $196,000 after purchasing an additional 639 shares in the last quarter. AlphaQuest LLC purchased a new stake in shares of Vera Therapeutics in the fourth quarter worth about $34,000. Alliancebernstein L.P. grew its stake in shares of Vera Therapeutics by 2.0% in the fourth quarter. Alliancebernstein L.P. now owns 40,350 shares of the company's stock valued at $1,706,000 after buying an additional 800 shares in the last quarter. Finally, E Fund Management Co. Ltd. raised its holdings in shares of Vera Therapeutics by 22.3% during the 4th quarter. E Fund Management Co. Ltd. now owns 6,203 shares of the company's stock valued at $262,000 after buying an additional 1,130 shares during the period. Institutional investors and hedge funds own 99.21% of the company's stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.